Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
Annals of Dermatology
;
: S314-S318, 2011.
Article
Dans Anglais
| WPRIM
| ID: wpr-165622
ABSTRACT
Vandetanib (ZD6474, Zactima(TM)) is a novel, orally available inhibitor of different intracellular signaling pathways involved in tumor growth, progression, and angiogenesis, including vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and rearranged during transfection tyrosine kinase activity. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QC interval prolongation, and hypertension. In a few randomized, double-blinded studies, cutaneous adverse events including these general symptoms have been reported, but there are only a few reports on the photosensitivity reaction to vandetanib domestically as conducted by dermatologists. In this report, we describe two cases of photosensitivity reactions induced by vandetanib. After improvement with steroid and antihistamine, the photosensitivity reaction was redeveloped by sequential treatment with docetaxel.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Pipéridines
/
Quinazolines
/
Protein-tyrosine kinases
/
Transfection
/
Récepteur-2 au facteur croissance endothéliale vasculaire
/
Taxoïdes
/
Diarrhée
/
Récepteurs ErbB
/
Hypertension artérielle
Type d'étude:
Essai clinique contrôlé
langue:
Anglais
Texte intégral:
Annals of Dermatology
Année:
2011
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS